
Dapaearth 10 Tab
D EARTH PHARMACEUTICALS - tablet - 10 S
Standard delivery
Distributor inventory | Tablet
Medically reviewed by Dr. Balaji Krishnan, MBBS · Updated June 2026
Dapagliflozin 5 mg + Sitagliptin 50 mg
Type 2 diabetes mellitus (to help control blood sugar in adults)
Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion via the kidneys. Sitagliptin is a DPP-4 inhibitor that increases incretin hormones, improving insulin release and reducing glucagon in a glucose-dependent manner.
Oral tablet; take exactly as prescribed, usually once daily at the same time each day, with or without food. Maintain adequate hydration; continue diet and exercise advice. Do not stop or change dose without medical advice.
Common side effects of Dapaearth-S 5/50MG Tab may include:

D EARTH PHARMACEUTICALS - tablet - 10 S
Standard delivery

D EARTH PHARMACEUTICALS - tablet - 10 S
Standard delivery

D EARTH PHARMACEUTICALS - tablet - 10 S
Standard delivery
D EARTH PHARMACEUTICALS - tablet - 1 mg - 10 S
Standard delivery

D EARTH PHARMACEUTICALS - tablet - 10 S
Standard delivery

D EARTH PHARMACEUTICALS - tablet - 10 S
Standard delivery

D EARTH PHARMACEUTICALS - tablet - 15 S
Standard delivery

D EARTH PHARMACEUTICALS - tablet - 15 S
Standard delivery
For type 2 diabetes only (not for type 1 diabetes). Risk of genital/urinary infections and dehydration; drink fluids and seek care for fever, burning urination or genital symptoms. SGLT2 inhibitors may rarely cause diabetic ketoacidosis even with near-normal sugars—seek urgent care for nausea/vomiting, abdominal pain, rapid breathing. Use caution in kidney disease; not recommended in severe renal impairment/end-stage kidney disease. May increase risk of hypotension in elderly/diuretics. Rare risk of pancreatitis with sitagliptin—seek care for severe abdominal pain. Inform doctor before surgery/acute illness; may need temporary stop. Monitor blood glucose and kidney function as advised.